Safety data from New ZealandBMJ 2009; 339 doi: https://doi.org/10.1136/bmj.b5654 (Published 31 December 2009) Cite this as: BMJ 2009;339:b5654
- Mira Harrison-Woolrych, director1
- 1Intensive Medicines Monitoring Programme, NZ Pharmacovigilance Centre, University of Otago, PO Box 913 Dunedin 9001, New Zealand
The recent letters on varenicline and suicide raise interesting issues about different approaches to identify and quantify risk in pharmacovigilance.1 2 In New Zealand the Intensive Medicines Monitoring Programme (IMMP)3 is currently performing an observational cohort study of varenicline. Our cohort is established directly from pharmacy dispensing data, which more accurately estimates varenicline exposure than prescription records …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial